about
High content screening for inhibitors of protein interactions and post-translational modifications in primary cells by proximity ligationIdentification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transportersLarge-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor SpheroidsPharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patientsInhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiramActivity of standard and investigational cytotoxic drugs in primary cultures of tumor cells from patients with kidney and urinary bladder carcinomasDrug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia.Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments.Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancerLabel-free detection and dynamic monitoring of drug-induced intracellular vesicle formation enabled using a 2-dimensional matched filter.In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index.Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system.Brunn: an open source laboratory information system for microplates with a graphical plate layout design process.Selective cytotoxicity evaluation in anticancer drug screening of fractionated plant extracts.Cyclotides: a novel type of cytotoxic agents.Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells.Screening of an annotated compound library for drug activity in a resistant myeloma cell line.Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model.Image-based screening for the identification of novel proteasome inhibitors.A Phase I study of CHS 828 in patients with solid tumor malignancy.Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients.Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data.Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells.Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia.Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic indexMechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity.Ex vivo activity of cardiac glycosides in acute leukaemia.Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment.Identification of agents that induce apoptosis of multicellular tumour spheroids: enrichment for mitotic inhibitors with hydrophobic properties.Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells.Novel activity of acriflavine against colorectal cancer tumor cells.Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells.The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan.Aminopeptidase N (CD13) as a target for cancer chemotherapy.Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology.Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan.Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives.Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma.
P50
Q24311672-82CC5C12-2432-45A2-91D0-2AC5BDC19284Q24648348-2DACA86F-4A58-44C3-8807-59619C649777Q27887660-0A7E2104-D247-4451-9EC9-2DF77D792ADBQ28267360-60D2BA6D-9998-4A74-BB51-EC8E601DF9BEQ28275643-198217FF-FDAC-4EFC-B515-925D7F330BC8Q28376685-04C0F0A8-B279-401F-AAF4-67693270850CQ30409637-62DFDA7E-52F0-4288-9104-EB15ABF1CD43Q30442799-AA568A8F-7646-48ED-919D-960B46C56BB7Q30446943-C4FA57F3-8F5E-4C43-AE1F-5C76DA062D70Q30560659-AC6C3078-94AA-4204-BD90-2B13308ABB4EQ30665874-EAB285D1-00FB-4748-931F-6549C3F28F91Q30855066-8C7223E3-5F51-4D0D-9795-1B20B45D3134Q31012969-C0FA89C5-8D66-4B3F-9DD6-1FFCD1B14A07Q31109328-AF7E9836-AB8F-4192-9FE4-088935BFF201Q31121086-26431738-9EC9-410D-BE8F-EF8CF7CEB942Q31882135-05F209A0-AD10-4804-966D-893BFA0BDA93Q33236010-3012881B-8111-4822-9274-3B9670DA783CQ33255029-A4814FE1-BF35-49EB-94A9-684CEC7D1EE6Q33268487-398EB2EF-AC4A-467A-B424-F9D5648E41FCQ33344280-7B4928CB-63EB-4B17-88DB-B169FEECE8A3Q33375758-A06F9B1F-C597-4F1F-8DF2-B8D7D0777676Q33386435-34849240-4BAE-41BF-93A2-01C2B0352505Q33507227-2D2B3BDC-F860-4EF4-9716-16C127B4D85CQ33585130-06361507-6E3D-4055-8C8C-2DA3F7CC6E9DQ33644858-A4532653-8351-4335-BA24-4B0D73290D82Q33728282-E287AA1C-8683-4578-97D9-3333F06218C4Q33796670-09217E84-5A47-4422-8547-9062A6B8DB73Q33885419-31D05803-4E28-43D2-B65A-0EFC53EEA3E4Q33949865-3E222002-FACE-401C-9FA2-A5B932736064Q33950327-38577835-6BF4-42E9-A750-04FCD522428EQ34017015-0319C89B-B153-4D88-8500-0E2D94748D16Q34031806-C1C75C86-472D-4042-903C-BD120C2B8D75Q34092354-A15AE053-09D0-475D-8956-B7718114B9C1Q34157418-1BEC764C-FB87-41DC-AE2C-E456ADC7A545Q34232133-FBDBE518-AB1C-4D93-ACA9-0211187EA9CFQ34264050-1907CA16-AAEA-4A30-8B24-2269943A07B4Q34282727-3B3D1465-8A68-494C-B6D7-536003EADCD0Q34294663-D60ECAB6-D4F5-4DAA-87D2-0580FF2A2FCAQ34338552-2BC14C41-EA21-4A6B-AE95-022B8F8B3235Q34354073-27C034D2-35DB-4433-8FC0-BC074BE8FD87
P50
description
Swedish researcher
@en
Zweeds onderzoeker
@nl
svensk kreftforsker
@nb
taighdeoir Sualannach
@ga
name
Rolf Larsson
@ast
Rolf Larsson
@da
Rolf Larsson
@de
Rolf Larsson
@en
Rolf Larsson
@es
Rolf Larsson
@fr
Rolf Larsson
@ga
Rolf Larsson
@nb
Rolf Larsson
@nl
Rolf Larsson
@nn
type
label
Rolf Larsson
@ast
Rolf Larsson
@da
Rolf Larsson
@de
Rolf Larsson
@en
Rolf Larsson
@es
Rolf Larsson
@fr
Rolf Larsson
@ga
Rolf Larsson
@nb
Rolf Larsson
@nl
Rolf Larsson
@nn
prefLabel
Rolf Larsson
@ast
Rolf Larsson
@da
Rolf Larsson
@de
Rolf Larsson
@en
Rolf Larsson
@es
Rolf Larsson
@fr
Rolf Larsson
@ga
Rolf Larsson
@nb
Rolf Larsson
@nl
Rolf Larsson
@nn